There was an increase in the levels of AH tetramer–positive tumor antigen–specific CD8+ TILs 7 days after treatment with combination therapy that was more pronounced than it was after treatment with mTAK-500 or PD-1 blockade alone (79.74% ± 5.61% in radiation plus mTAK-500 vs. 60.41 ± 4.61 in mTAK-500–treated animals and 55.36 ± 7.51 in vehicle-treated animals; Fig. 5D). Here, CD8A is linked to neoplasm.